-
Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon
Wednesday, November 16, 2022 - 1:47pm | 378Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has begun screening subjects for its Phase 1 clinical study on the IV formulation of its DMT compound AP-188 in the Netherlands. CEO Christopher J. Moreau said the company is thrilled to initiate...
-
DiaMedica Stock Gains On Green Signal To Start Pivotal DM199 Trial In Ischemic Stroke
Monday, May 17, 2021 - 12:28pm | 180The FDA has signed off DiaMedica Therapeutics Inc's (NASDAQ: DMAC) Investigational New Drug (IND) application to proceed with a pivotal Phase 2/3 study of DM199 (recombinant human tissue kallikrein-1or KLK1) for the treatment of patients with Acute Ischemic Stroke (AIS)....
-
'Spider-Man' Glenn King Hopes His Potential Stroke-Saving Arachnid Molecule Makes It To Market
Friday, March 24, 2017 - 1:50pm | 1157The journey is just beginning for Glenn King, a researcher whose team found that the world’s most poisonous spider could provide fast treatment for stroke victims and stop their brain cells from burning out. The initial findings were presented this week in the journal Proceedings of the...
-
Lesson Learned: Don't Trust Twitter Users With A Multi-Billion-Dollar Secret
Wednesday, June 15, 2016 - 10:46am | 324Novo Nordisk A/S (ADR) (NYSE: NVO) presented data at the American Diabetes Association on Monday and trusted the doctors in attendance to not share the confidential and market-moving data they just saw. As if that would actually happen in the modern day of smartphones and social media....